Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma

Glioblastomas are among the most fatal brain tumors. Although no effective treatment option is available for recurrent glioblastomas (GBMs), a subset of patients evidently derived clinical benefit from bevacizumab, a monoclonal antibody against vascular endothelial growth factor. We retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Seung Won, Shin, Hyemi, Sa, Jason K., Cho, Hee Jin, Koo, Harim, Kong, Doo‐Sik, Seol, Ho Jun, Nam, Do‐Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943425/
https://www.ncbi.nlm.nih.gov/pubmed/29573206
http://dx.doi.org/10.1002/cam4.1439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943425/
https://www.ncbi.nlm.nih.gov/pubmed/29573206
http://dx.doi.org/10.1002/cam4.1439

Ejemplares similares